Cargando…
Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
Autores principales: | Lee, Dawn, Thornton, Patrick, Hirst, Alexander, Kutikova, Lucie, Deuson, Robert, Brereton, Nic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079584/ http://dx.doi.org/10.1007/s40258-013-0066-5 |
Ejemplares similares
-
Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013) -
Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016) -
Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022) -
Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023) -
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)